Boston Scientific Leads The Charge For Stem Cell Alliances With Osiris Stake
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's investment in stem cell therapy developer Osiris Therapeutics may signal a wave of device/biotech collaborations related to delivery techniques for stem cell treatments
You may also be interested in...
Cardiac Stem Cell Alliances Include Large Firms; MacroPore “Grows” It Alone
MacroPore Biosurgery insists it will pursue solo development of stem cell therapy for myocardial infarction, even though competitors are increasingly aligning with large cardiovascular device firms
Cardiac Stem Cell Alliances Include Large Firms; MacroPore “Grows” It Alone
MacroPore Biosurgery insists it will pursue solo development of stem cell therapy for myocardial infarction, even though competitors are increasingly aligning with large cardiovascular device firms
New Kid On The Block: Pfizer/Pharmacia Merger Points To Drug-Device Play
Pfizer will leverage its acquisition of Pharmacia to carve out a combination drug-device business to support its needle-less insulin delivery initiatives